Biotinylated Human Her2, His,Avitag (HE2-H82E2) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # P04626-1).
Predicted N-terminus: Thr 23
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.
The protein has a calculated MW of 73.0 kDa. The protein migrates as 85-95 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Less than 1.0 EU per μg by the LAL method.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human Her2, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Trastuzumab at 3 μg/mL (100 μL/well) can bind Biotinylated Human Her2, His,Avitag (Cat. No. HE2-H82E2) with a linear range of 0.2-6 ng/mL (QC tested).
Biotinylated Human Her2, His,Avitag (Cat. No. HE2-H82E2) immobilized on SA Chip can bind Herceptin® with an affinity constant of 17 pM as determined in a SPR assay (Biacore T200) (Routinely tested).
2e5 of Anti-Her2 CAR-293 were stained with 100 μL of 1 μg/mL of Biotinylated Human Her2 Protein, His,Avitag™ (Cat. No. HE2-H82E2) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).
Authors: Chatterjee Sohang , et al
Journal: US20200149032A1 2020
Application: Flow Cytometry
Authors: NR Sundah, et al
Journal: Nat Biomed Eng 2019
Authors: YM Kim, et al
Journal: US20180360986A1 2019
Authors: Lobb Roy, et al.
Journal: US20180142035A1 2018
Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .